Vident Investment Advisory, LLC Supernus Pharmaceuticals, Inc. Transaction History

Vident Investment Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $199,439 - $258,251	6,668 New	6,668 $200,000
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $28,318 - $38,291	-1,118 Reduced 7.96%	12,919 $374,000
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $23,948 - $27,636	-840 Reduced 5.65%	14,037 $453,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $141,686 - $183,864	5,373 Added 56.53%	14,877 $434,000
Q3 2021 Nov 12, 2021	SELL	$23.54 - $31.39 $136,037 - $181,402	-5,779 Reduced 37.81%	9,504 $253,000
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $142,978 - $177,599	5,351 Added 53.88%	15,283 $471,000
Q1 2021 May 14, 2021	SELL	$24.15 - $31.45 $14,997 - $19,530	-621 Reduced 5.88%	9,932 $260,000
Q4 2020 Feb 08, 2021	SELL	$17.7 - $25.81 $5,221 - $7,613	-295 Reduced 2.72%	10,553 $266,000
Q3 2020 Nov 12, 2020	BUY	$20.2 - $25.05 $219,129 - $271,742	10,848 New	10,848 $226,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.